stocks

Prime Stock recommendation: A pharma stock available at a bargain

Picking a stock in the pharma space is not easy. The businesses are complex and can leave you feeling like you are preparing for a mini-MBBS. Whatโ€™s more โ€“ no two companies are alike. To compound matters, it is also a heavily regulated space (and rightly so) with complex supply chains very often, heavily reliant on China. Not only do most end products have names that sound like tongue twisters but can be governed by complex patent regulations.

Premium article available only to subscribers.

Prime Stock recommendation: A pharma stock available at a bargain Read More ยป

Entering a stock at peak valuation? โ€“ 5 questions to ask

When markets make merry, many stocks have seemingly compelling stories even for entering at peak valuation. And the market is fine with stretched valuations to accommodate such stories. In other words, every market-favoured stock appears to scream – buy me at any price.

But when challenges emerge, the same market starts reacting so sharply that investors who bought into the story midway start making losses. Yes, there isnโ€™t a bigger disaster for stock market investors than earnings and PE multiples contracting together.

Entering a stock at peak valuation? โ€“ 5 questions to ask Read More ยป

Why banking is a fragile business

The recent furore surrounding the failure of Silicon Valley Bank in the US has exposed that while banking is a favourite sector with stock market investors, the fragility of the banking business is far from well-understood. Banks are held up as the engines of economic growth. Whichever sector grows, the banking sector ultimately gains. Banks are also accorded a higher valuation than most sectors during bull phases. In good times, banks made up a 40% plus weight in our leading stock market indices.

Why banking is a fragile business Read More ยป

Prime Stock: An averaging call on this fashion player

In February last year, we had issued a buy call on the stock of a premier fashion player housing a vast number of national brands. The steps this company had taken to expand its offering range, a return of focus on margins, and the consumption promise all propelled the call. the stock rallied handsomely as well, post our call.
However, owing to two factors, the stock has since given up nearly 40% from its high and is currently about 25% below our original call price.

Prime Stock: An averaging call on this fashion player Read More ยป

Prime Stock alert: Shifting this auto stock from HOLD to BUY

Indian markets have corrected about 10% (Nifty 50) from the last peak in December 2022. But many stocks have fallen much more than the bellwether index. This has provided an opportunity to revisit some of our recommended stocks โ€“ to either identify averaging opportunities or move them to a BUY from a HOLD.

Premium article available only to subscribers.

Prime Stock alert: Shifting this auto stock from HOLD to BUY Read More ยป

Prime Stock recommendation: A promising play on food security

Recent instances of countries rationing food supplies on import disruptions and grappling with hyper-inflation, have prompted governments the world over to refocus on food security. With limited supply of arable land and water, the key to achieving food security lies in improving crop yields. In India, thereโ€™s a crying need to improve yields not only to secure food supplies for the domestic population, but also to cater to global export opportunities for farm products, that are at an inflection point. Companies engaged in crop protection, fertilizer and hybrid seeds are positioned to make the most of these tailwinds.
But if youโ€™re an Indian investor looking to make a long-term bet on this theme, your options arenโ€™t very many. There are about 20 listed companies in the fertilizer space. But the sector makes for a poor investment because of whimsical government policies that hamper growth and profitability. Listed crop protection and seed companies offer superior options. Listed agrochem players offer choices from micro to large players, with differing business models that focus on generic agrochemicals, interm

Premium article available only to subscribers.

Prime Stock recommendation: A promising play on food security Read More ยป

Technical outlook: Can the Nifty 50 slide further?

In the past couple of posts on the Nifty 50 outlook, we have been voicing a bearish view for the Nifty 50 index. This has played out as per expectations. The index almost achieved the first target of 17,150-17,200 that was mentioned a couple of posts ago. In the previous update, we had mentioned the possibility of a slide to the 16,700-16,900 zone.
Let us assess if this target is likely to be achieved or not.

Technical outlook: Can the Nifty 50 slide further? Read More ยป

Prime stock update: Are we still sweet on this sugar maker?

In August 2021, we recommended a sugar manufacturer, well placed to play the ethanol opportunity that was set to change the dynamics of the sugar sector in India. 18 months down the line, the ethanol opportunity has played out as we expected and we have more clarity on this front. But at the same time, stock returns for our chosen candidate stand at just ~5% since our โ€˜BUYโ€™ recommendation even though it rallied over 30% and also fell by almost 20% in the interim. We think, this calls for an update.

Premium article available only to subscribers.

Prime stock update: Are we still sweet on this sugar maker? Read More ยป

Prime stocks update: An exit call on an insurance stock

In April 2022, we had issued a buy recommendation on a general insurance player, as both the industry and the company itself were emerging from the Covid-driven impact and were poised for growth. Since then, however, the insurance sector has lost market favour as growth has not panned out as expected.

Premium article available only to subscribers.

Prime stocks update: An exit call on an insurance stock Read More ยป

Prime Stocks update: Moving this biotech stock from BUY to a HOLD

When we gave the call of this R&D focused company engaged in the manufacture of enzymes and probiotics, the company had Covid-related challenges but showed promise of growth. It was later also pulled down by consolidation of acquisitions and costs related to new product launches. We therefore knew that the call would take longer to pay off.ย  The stock went through a significant correction after our initial recommendation as earnings disappointed.

Premium article available only to subscribers.

Prime Stocks update: Moving this biotech stock from BUY to a HOLD Read More ยป

Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

or
Have an account?
Login To Your Account
OR
Donโ€™t have an account ? Register for free